Active, not recruitingNot applicableInterventional
What this study is about
This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. The study includes body measurements, questionnaires, blood tests, and CGM monitoring to assess metabolic outcomes and participant-reported perceptions of well-being.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 70 Years
SexAll
Healthy volunteersAccepted
ConditionOverweight, Metabolic Health, Insulin Resistance
Full registry criteria
Inclusion Criteria: * Be male or female * Be aged between 18 and 70 years of age * Be classified as overweight or obese with a BMI of ≥25.0 and ≤32 kg/m2. * Have a stable weight defined as \<10% change in body weight in three months prior to the study start date. * Willing to follow the provided diet and exercise guidelines. * Willing to not consume avocados throughout the trial and for two weeks prior to Baseline * Anyone who is generally healthy - does not live with any uncontrolled chronic disease. * Willing to stop any products, any prescription medication, or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period. * Willing to avoid introducing any new products or any new forms of prescription medication or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period. * Not currently partaking in another research study and will not be partaking in any other research study for the next 16 weeks and at any point during this study's duration. * Must have someone available to take front and side profiles of the torso. * Must have a smart phone or camera capable of taking photos of the torso. * Resides in the United States. Exclusion Criteria: * Anyone with diagnosed Type I or Type II diabetes. * Allergic to avocados * Anyone with any allergies or sensitivities to any of the study product ingredients. * Any women who are pregnant, breastfeeding, or trying to conceive * Anyone unwilling to follow the study protocol. * Has stopped using hormonal birth control in the past month. * Anyone with a history of substance abuse. * Anyone who is currently a smoker or has been a smoker in the past 6 months. * Anyone with chronic health conditions that could impact participation in the study, such as oncological, psychiatric, metabolic, hypertension, or cardiovascular disorders, cancer, autoimmune disease, HIV, Hepatitis B, and/or C, kidney and/or liver, gastrointestinal, gastroesophageal reflux, blood/bleeding disorders, gout, or mental health disorders. * Anyone who has had any major illness in the last 3 months. * Anyone who drinks heavily (i.e., 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men). * Current use of prescribed medications as listed below: Weight loss prescription medication (within 3 months of baseline). Anticoagulants and coagulants (within 4 weeks of baseline). * Anyone who has used any cannabis products (medical or recreational) in the past month.
Primary outcomes
Change in Body MassBaseline through Week 16Measured via Withings Smart Scale. Participants will weigh themselves daily for 3 consecutive days each week. If the first two values are similar, their average is used. If they differ by ≥10 lbs, the third value is used to determine the average.
Change in Average Blood Glucose2 weeks before Baseline and Weeks 14-16Change in average blood glucose levels measured using a Continuous Glucose Monitor (CGM). Average glucose will be calculated over each time period and the change from pre-baseline to Weeks 14-16 will be reported.
Change in Hemoglobin A1C (HbA1C)Baseline and Week 16Assessed via blood samples at Labcorp or via home phlebotomy.
Change in Fasting InsulinBaseline and Week 16Assessed via blood samples at Labcorp or via home phlebotomy.
Change in Lipid PanelBaseline and Week 16Includes Cholesterol, LDL, VLDL, HDL, and triglycerides. Measured via Labcorp or home phlebotomy.
Change in hs-CRPBaseline and Week 16High-sensitivity C-reactive protein measured via Labcorp or home phlebotomy.
Change in Fasting GLP-1 LevelsBaseline and Week 16Only measured in the home phlebotomy subgroup using InterScience Institute lab testing.
Change in Waist CircumferenceBaseline, Week 2, Week 4, Week 8, Week 12, Week 16Measured with a tape measure.
